TAR-200 PDUFA Date (Johnson & Johnson)
FDA PDUFA decision date for TAR-200 is January 3, 2026. Developed by Johnson & Johnson. Indication: BCG-unresponsive high-risk non-muscle invasive bladder cancer. Current status: Approved.
Indication
BCG-unresponsive high-risk non-muscle invasive bladder cancer
Regulatory details
- Company: Johnson & Johnson
- Therapeutic area: Oncology / Urology
- Application type: NDA
- Review type: Priority
- PDUFA date: 2026-01-03
- Outcome: Approved